Pathophysiological underpinnings of multiple myeloma progression
1New York Medical College, New York, NY 10011, USA. sjagannath@aptiumoncology.com
Journal of Managed Care Pharmacy : JMCP
|November 1, 2008
Summary
Multiple myeloma (MM) is a bone marrow cancer characterized by plasma cell proliferation. Advances in understanding its genetics and microenvironment are improving diagnosis, treatment, and patient survival.
Area of Science:
- Hematology
- Oncology
- Genetics
Background:
- Multiple myeloma (MM) is a plasma cell malignancy in the bone marrow, causing skeletal destruction, renal failure, hypercalcemia, and anemia.
- While incurable, recent insights into the bone marrow microenvironment and cytogenetics are improving MM treatment strategies, remission duration, and survival rates.
Purpose of the Study:
- Review MM pathophysiology, genetic factors, risk factors, and disease progression.
- Address MM diagnosis, staging, classification, complications, and the roles of cytogenetic abnormalities and the bone marrow milieu.
Main Methods:
- Review of current literature on multiple myeloma.
- Analysis of diagnostic criteria, staging systems (e.g., International Staging System - ISS), and classification.
- Examination of the impact of cytogenetic abnormalities and bone marrow microenvironment on disease progression and treatment.
Main Results:
- Malignant plasma cells produce monoclonal protein, stimulating osteoclasts, leading to bone resorption, lesions, and hypercalcemia.
- Myeloma cells disrupt normal bone marrow function, causing renal insufficiency, anemia, infection, and clotting disorders.
- Updated diagnostic standards and the ISS provide a 3-tiered classification based on serum albumin and beta2-microglobulin; cytogenetic testing is crucial for personalized treatment.
Conclusions:
- Therapeutic targets within the bone marrow microenvironment are driving new MM treatments.
- Addressing comorbid conditions improves quality of life for MM patients.
- Ongoing research and evolving standards of care are rapidly advancing MM patient outcomes.
Related Concept Videos
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
02:07Tumor Progression
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
01:15Differentiation of Common Myeloid Progenitor Cells
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...